IPO Tracker
Lifecycle-aware IPO monitoring from filing interest through post-listing evidence.
A small, manually selected starter list tracking upcoming, filed, priced, listed, and post-listing names without mixing them into standard AnalystScope coverage before the data quality is ready.
Manual tracker, source-backed where possible
Entries use SEC identifiers, exchange quote pages, and clearly labelled market-reporting context where available. AnalystScope readiness, valuation posture, risks, and promotion judgment remain manual. This is not a live IPO feed, not a recommendation engine, and not personal investment advice.
Automation boundary
The internal checker can inspect known tracked CIKs, review-state flags, and the separate IPO quote artifact. It does not publish new IPO entries, change valuation posture, generate fair values, or promote names into standard coverage.
Tracked entries
5
Small, curated universe only.
SEC-backed entries
5
CIK/entity context on file.
Post-listing tracking
5
Not standard coverage by default.
IPO quote artifact
5/0/0
Fresh / stale / pending, separate from coverage quotes.
Objective review needed
2
Triggered by quote, source, range, or data-quality checks.
Lifecycle buckets
Where each tracked name stands
Quotes and source checks can refresh automatically. Signals and preliminary fair values remain manual/model-reviewed.
Upcoming / filed
0Rumoured names and companies with public filing context.
Priced / listing soon
0Offer terms exist, but public trading evidence is not complete.
Recently listed
3Source-backed listings within the last 12 months.
Older monitored
2Post-listing names outside the first-year window or awaiting date verification.
Lifecycle view
The Tracker separates lifecycle stage from AnalystScope readiness. A listed IPO can still be watch-only if disclosure, quote handling, or normalized statements are not yet strong enough.
Browse filters
Promotion rule
IPO Tracker names do not become standard AnalystScope coverage just because a ticker exists. Promotion requires stable quote handling, enough public reporting, normalized statement support, and defendable model assumptions.
Stable ticker, exchange, public float, and share-count treatment.
Enough SEC filing and reporting history to normalize revenue, margin, cash flow, and dilution.
A defendable bridge from IPO disclosures to durable public-company economics.
Quote handling that can support performance tracking without mixing the name into standard coverage too early.
Tracked IPOs
1 of 5 entries match the current filters. Every row is a manual Tracker artifact, even when SEC or exchange links are attached.
Hinge Health
Last reviewed Apr 7, 2026
Latest manual update
Readiness improved after a cleaner early read on growth and margin profile, but retention and employer durability still need more proof.
Automated maintenance state
Manual valuation review required
Current price is outside the manual 38-65 preliminary range. The retained range was reviewed at $67.04, and the quote has moved 17.8% since that review.
Valuation review needed
Current quote is outside the manual valuation range. This flags owner review only; it does not update the IPO signal, confidence, or valuation range automatically.
Automated checks may refresh quotes and source/review metadata only. The IPO signal, confidence, and fair-value range remain manual/model-reviewed.
Source-backed context
SEC entity mapping and NYSE quote context are available. Readiness depends on retention, employer adoption, and margin durability.
IPO research view
The business profile is more legible than many digital-health IPOs and could become model-ready, but the current quote still needs to be tested against retention, employer economics, and margin durability before AnalystScope would use a stronger positive signal.
SEC entity context, NYSE quote page, IPO offer context, and current IPO quote artifact support market monitoring; first-close and multiple reporting periods still need manual review.
Preliminary valuation layer
Manual peer-multiple range using software-enabled care, digital-health, and employer-benefit platform comparables, discounted for limited public reporting history.
Quote artifact updates objective prices only. IPO signals, peer ranges, and valuation interpretation remain manually reviewed and do not promote this ticker into standard coverage.
Fair-value range
$38.00 / $50.00 / $65.00
A quote above the high end of this preliminary range does not automatically mean sell; it means the stock needs more retention and margin proof before stronger conviction.
Base vs offer
+56.3%
Base vs current
-36.7%
Current marker appears only when the separate IPO quote artifact has source-tagged data. Marker positions are clipped to the displayed range to avoid implying precision beyond the manual low/base/high view.
Post-listing performance
Source-tagged IPO Tracker quote is inside the daily freshness window.
Separate IPO quote artifact
Current price is sourced from Yahoo Finance market quote as of Jun 27, 2026, 07:15 AM UTC. This quote does not enter standard AnalystScope coverage or homepage quote gates.
Offer price
$32.00
Source-backed
First close
Pending
Pending
Current price
$78.97
Quote-tracked | Jun 27, 2026, 07:15 AM UTC
Current vs offer
+146.8%
Based on source-tagged IPO Tracker quote data.
Current vs first close
Pending
Shown only when first-close and current quote data are both source-backed.
Days since IPO
401
Listing date May 22, 2025
What the business is
Software-enabled musculoskeletal-care platform combining digital engagement, provider delivery, and employer-backed health spend.
What matters fundamentally
Retention, employer economics, contribution margin durability, and how much current profitability depends on unusually favorable mix or timing are the core fundamentals to test.
Fundamental snapshot
Early IPO fundamentals stay separate from standard AnalystScope normalized statements. Pending fields remain visible as manual tie-out items rather than being filled with placeholder math.
Revenue
Disclosure exists in public filings; growth quality requires continued reporting review.
Growth
Visible but still needs durability proof across more public periods.
Gross margin
Unavailable / pending manual tie-out
Operating margin
Unavailable / pending manual tie-out
Net income / loss
Unavailable / pending manual tie-out
Cash flow / burn
Unavailable / pending manual tie-out
Cash
Unavailable / pending manual tie-out
Debt
Unavailable / pending manual tie-out
Implied market cap
Pending; current quote and share-count bridge require manual tie-out.
EV / Sales
Pending; EV bridge and revenue base need manual tie-out.
EV / Gross profit
Pending; gross-profit disclosure needs manual review.
Profitability
Early profitability evidence is promising but not yet durable enough for full coverage.
Use of proceeds
Unavailable / pending manual tie-out
Governance / control
Manual review required.
Lock-up / float
Material; early IPO float and lock-up supply may affect price discovery.
Concentration
Employer/channel concentration and retention require ongoing review.
Peer group
Peer multiple frame
Manual revenue/margin multiple range; broad because profitability durability is not settled.
Peer comparison read
Current quote needs to be compared against a wide range rather than a single target because margin durability remains unproven.
Why peers are imperfect
Pure software peers overstate scalability, while healthcare-services peers may understate software-enabled margin potential.
Business quality comparison
Higher-quality than many digital-health watch names if retention and employer ROI hold, but evidence is still short of full coverage.
Filing / disclosure summary
SEC ticker mapping and public filings exist for HNGE. The entry is closer to model readiness, but still needs more reporting history before standard coverage.
Financial disclosure Public filings exist and the operating story is more legible than many digital-health listings, but retention and employer economics still need more proof.
What still needs to be seen
More public evidence on retention, employer economics, margin durability, and whether early profitability holds up without depending on one unusually favorable period.
Confidence trigger More proof that retention, employer adoption, and margin improvement hold across multiple reporting periods, not just the first public read.
Valuation posture
Model-ready soon
Early fair-value work is becoming plausible, but it still belongs in a restrained range-building posture rather than a full published rating.
Key risks / blockers
Employer demand, retention, and engagement durability still need public-market proof.
Digital-health margin improvement can reverse if service intensity rises.
Reimbursement and buyer-budget sensitivity can change quickly.
Recent trail
What the internal checker can do
The protected IPO checker is designed to inspect known tracked CIKs for SEC filing changes, compare them against the local Tracker metadata, and report which entries need manual review. It is intentionally a review assistant, not a publishing workflow.
Report newer SEC filing metadata when available.
Flag stale manual reviews and entries with manual-review-required.
Surface listed tickers that still lack quote-tracking readiness.
Avoid changing valuation posture, fair value, or standard coverage status.
What this page is not
IPO Tracker is not a live IPO calendar, not a scraped news feed, and not a shortcut into standard AnalystScope coverage. A listed ticker can be tracked here for months while AnalystScope waits for cleaner reporting, normalized statement support, and defensible valuation assumptions.
Route compatibility remains /ipo-watch, but the product label and mental model are now IPO Tracker.